MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Effect of Aspartame on Parkinson’s Disease Progression and Severity

    D. Kushigian, O. Vaou (Boston, USA)

    Objective: The purpose of this review was to assess the current evidence regarding the effect of aspartame (APM) consumption on Parkinson’s Disease (PD) severity. Background:…
  • 2022 International Congress

    Body-first and brain-first PD animal models mimic human PD subtypes

    N. Vanden Berge, M. Pedersen, I. Klæstrup, J. Jacobsen, M. Simonsen, A. Alstrup, M. Romero-Ramos, P. Borghammer (Aarhus N, Denmark)

    Objective: Here, we aim to model body- and brain-first PD by injecting pathology in the gut and amygdala of old wild-type rats, respectively. Background: Parkinson’s…
  • 2022 International Congress

    The Effect of a Boxing Exercise Program on Laryngeal Function in People with Parkinson’s Disease

    Z. Thijs, C. Watts (Fort Worth, USA)

    Objective: This project aimed to determine the effect of a boxing exercise program on aerodynamic measures related to voice production (maximum expiratory pressure, MEP; transglottal…
  • 2022 International Congress

    Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease

    I. Frouni, W. Kang, D. Bédard, L. Desbiens, C. Kwan, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…
  • 2022 International Congress

    Differences between two cognitive assessment instruments used in Parkinson’s disease in Kyrgyzstan

    E. Zhunusova, C. Shambetova, A. Il'Yazova (Bishkek, Kyrgyzstan)

    Objective: The aim of this study was to determine differences between Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in PD patients from Kyrgyzstan.…
  • 2022 International Congress

    Fatigue at different stages of parkinson’s disease

    A. Tohirjonova, м. Tohirjonov (Tashkent, Uzbekistan)

    Objective: study fatigue as a key non-motor symptom of parkinson's disease Background: Fatigue in PD refers to a state of fatigue, lack of energy, a…
  • 2022 International Congress

    Cognitive-motor tests markedly increase the diagnostic rate of “On-meds” freezing of gait in Parkinson’s disease during clinical visits

    Z. Pei (Guangzhou, China)

    Objective: To develop a testing and recording system that can reliably increase the rate of diagnosing freezing of gait (FOG) in patients living with Parkinson’s…
  • 2022 International Congress

    Common mistakes in the MoCA test in patients with Parkinson’s Disease in Kyrgyzstan

    A. Il'Yazova, C. Shambetova, E. Zhunusova (Bishkek, Kyrgyzstan)

    Objective: The aim of the study is to identify common mistakes in MoCA in patients with Parkinson’s disease (PD) in Kyrgyzstan. Background: Cognitive impairment is…
  • 2022 International Congress

    Changes in anticholinergic burden in patients with Parkinson’s disease (PD) after bilateral deep brain stimulation (DBS) of the globus pallidus (GP) and subthalamic nucleus (STN)

    J. Jiao, M. Wilheimi, B. Brumbach, D. Safarpour (Portland, USA)

    Objective: To evaluate the effect of GP and STN DBS upon anticholinergic medication burden in patients with PD. Background: Medications with anticholinergic effects are commonly…
  • 2022 International Congress

    The level of glial neurotrophic factor in blood plasma depending on the stage of Parkinson’s disease

    R. Matmurodov, M. Muminov, A. Abduqodirov, K. Khalimova (Tashkent, Uzbekistan)

    Objective: To study the level of glial neurotrophic disease in blood plasma in patients with Parkinson's disease (PD) depending on the stage Background: Parkinson's disease…
  • « Previous Page
  • 1
  • …
  • 211
  • 212
  • 213
  • 214
  • 215
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley